Ph.D., Chief Technology Officer, Boundless Bio
Biography
Jason Christiansen has served in multiple positions leading the development of new technologies and strategies for their research and diagnostic use. He has served as Head of Assay Development at Roche Sequencing Solutions, providing leadership in initiatives around oncology testing, Dx development, NIPT testing and platform development. Prior to Roche, Jason was VP of Diagnostics at Ignyta, where he led CDx development efforts including an in-house CLIA laboratory and molecular testing R&D group working both internally and externally to drive molecular testing in support of a global clinical trial for entrectinib. Prior to Ignyta, Jason served in multiple senior positions developing new platforms and technologies in NGS, digital pathology and molecular testing so that they could be brought into the clinical laboratory for patient testing and to support drug development.
Emerging Therapeutics Showcase:
Boundless Bio, Inc.
Boundless Bio, is a San Diego based company discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.
Targeting Extrachromosomal DNA (ecDNA), A New Approach To Targeting Cancers With High Copy Number Amplification
Cancers driven by genetic amplification are dominated by poor prognosis and have been a problematic target for therapeutics to date. However, the recent elucidation of ecDNA as a mechanism for supporting high copy number cancers and driving tumor heterogeneity has also provided insight on previous therapeutic failures and new avenues for potential treatment. Using multiple laboratory approaches, new ecDNA specific targets can be identified to precisely select patient groups and provide new treatments.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 23 2.00 P.M.-3.45 P.M.,Track 6 - January 24 10.30 A.M.-4.30 P.M.
The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
